Takeda continues to pursue the transformation of its R&D activities, which has already led to expansion of the pipeline, but will continue with core strategies including partnering even after the huge Shire acquisition.
Just over two years into its five-year effort to fundamentally transform its R&D activities, Takeda Pharmaceutical Co. Ltd. says the initiative has led to a more focused approach and an enlarged pipeline, fueled by an open approach to partnering.
With a global emphasis on oncology, gastroenterology, neuroscience and vaccines, the company's drug discovery units have been halved over the...
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.
With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.
The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available.
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.
Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.
